The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Neuroblastoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
The International Neuroblastoma Pathology Classification (the Shimada system)
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Targeted expression of MYCN causes neuroblastoma in transgenic mice
Weiss, W. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.2985 · Cited by 870
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870
Shimada, H., Chatten, J., Newton, W. A., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., & Misugi, K. (1984) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/73.2.405 · Cited by 862
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Huang, M., & Weiss, W. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014415 · Cited by 647
Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer
Reid, S., Schindler, D., Hanenberg, H., Barker, K., Hanks, S., Kalb, R., Neveling, K., Kelly, P., Seal, S., Freund, M., et al. (2007) · Nature Genetics · doi:10.1038/ng1947 · Cited by 642
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Neuroblastoma: Biology, Prognosis, and Treatment
Park, J. R., Eggert, A., & Caron, H. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.011 · Cited by 620
Self-citationBrodeur, G. M., Seeger, R. C., Barrett, A., Berthold, F., Castleberry, R. P., D'Angio, G., De Bernardi, B., Evans, A. E., Favrot, M., & Freeman, A. I. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1874 · Cited by 608
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Self-citationLook, A. T., Hayes, F. A., Shuster, J. J., Douglass, E. C., Castleberry, R. P., Bowman, L. C., Smith, E. I., & Brodeur, G. M. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.581 · Cited by 594
London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, H., Thorner, P., Brodeur, G., Maris, J. M., Reynolds, C. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.571 · Cited by 589
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Cheung, N.-K. V. (2012) · JAMA · doi:10.1001/jama.2012.228 · Cited by 468
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467
Neuroblastoma Screening at One Year of Age
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing
Hovestadt, V., Jones, D. T. W., Picelli, S., Wang, W., Kool, M., Northcott, P. A., Sultan, M., Stachurski, K., Ryzhova, M., Warnatz, H.-J., et al. (2014) · Nature · doi:10.1038/nature13268 · Cited by 450
DeBaun, M. R., & Tucker, M. A. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70008-3 · Cited by 437
Allelic Loss of Chromosome 1p as a Predictor of Unfavorable Outcome in Patients with Neuroblastoma
Caron, H. N., Sluis, P. V., de Kraker, J., Bökkerink, J. P. M., Egeler, M., Laureys, G., Slater, R. M., Westerveld, A., Voûte, P. A., & Versteeg, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340404 · Cited by 425
Sausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A., Parmigiani, G., Diaz, L. A., Papadopoulos, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2493 · Cited by 414
Ambros, P. F., Ambros, I. M., Brodeur, G. M., Haber, M., Khan, J., Nakagawara, A., Schleiermacher, G., Speleman, F., Spitz, R., London, W. B., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605014 · Cited by 404
Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70291-6 · Cited by 402
SPECIAL PATTERN OF WIDESPREAD NEUROBLASTOMA WITH A FAVOURABLE PROGNOSIS
D'Angio, G., Evans, A., & Koop, C. E. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91606-0 · Cited by 401
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 365
Germline Mutations of the Paired–Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., Schleiermacher, G., Coze, C., Philip, N., Frébourg, T., Munnich, A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383253 · Cited by 358
Screening of Infants and Mortality Due to Neuroblastoma
Woods, W. G., Gao, R.-N., Shuster, J. J., Robison, L. L., Bernstein, M., Weitzman, S., Bunin, G., Levy, I., Brossard, J., Dougherty, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012387 · Cited by 356
Copy number variation at 1q21.1 associated with neuroblastoma
Diskin, S. J., Hou, C., Glessner, J. T., Attiyeh, E. F., Laudenslager, M., Bosse, K., Cole, K., Mossé, Y. P., Wood, A., Lynch, J. E., et al. (2009) · Nature · doi:10.1038/nature08035 · Cited by 354
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Janoueix-Lerosey, I., Schleiermacher, G., Michels, E., Mosseri, V., Ribeiro, A., Lequin, D., Vermeulen, J., Couturier, J., Peuchmaur, M., Valent, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0630 · Cited by 349
Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1
Brems, H., Beert, E., de Ravel, T., & Legius, E. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70033-6 · Cited by 349
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Park, J. R., Bagatell, R., London, W. B., Maris, J. M., Cohn, S. L., Mattay, K. M., Hogarty, M., & on behalf of the COG Neuroblastoma Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24433 · Cited by 332
Self-citationthe CPNDS Consortium, Ross, C. J. D., Katzov-Eckert, H., Dubé, M.-P., Brooks, B., Rassekh, S. R., Barhdadi, A., Feroz-Zada, Y., Visscher, H., Brown, A. M. K., et al. (2009) · Nature Genetics · doi:10.1038/ng.478 · Cited by 327
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 326
Chen, Y., & Stallings, R. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3667 · Cited by 326
Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma
Maris, J. M., Mosse, Y. P., Bradfield, J. P., Hou, C., Monni, S., Scott, R. H., Asgharzadeh, S., Attiyeh, E. F., Diskin, S. J., Laudenslager, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708698 · Cited by 319
London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3392 · Cited by 318
Hero, B., Simon, T., Spitz, R., Ernestus, K., Gnekow, A. K., Scheel-Walter, H.-G., Schwabe, D., Schilling, F. H., Benz-Bohm, G., & Berthold, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3349 · Cited by 311
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Wang, K., Diskin, S. J., Zhang, H., Attiyeh, E. F., Winter, C., Hou, C., Schnepp, R. W., Diamond, M., Bosse, K., Mayes, P. A., et al. (2011) · Nature · doi:10.1038/nature09609 · Cited by 310
Trk Receptor Expression and Inhibition in Neuroblastomas
Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V., & Evans, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1815 · Cited by 307
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Capasso, M., Devoto, M., Hou, C., Asgharzadeh, S., Glessner, J. T., Attiyeh, E. F., Mosse, Y. P., Kim, C., Diskin, S. J., Cole, K. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.374 · Cited by 305
Kreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Self-citationArceci, R. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79165-6 · Cited by 299
Oberthuer, A., Berthold, F., Warnat, P., Hero, B., Kahlert, Y., Spitz, R., Ernestus, K., König, R., Haas, S., Eils, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1879 · Cited by 291
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
Germline PHOX2B Mutation in Hereditary Neuroblastoma
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284
De Brouwer, S., De Preter, K., Kumps, C., Zabrocki, P., Porcu, M., Westerhout, E. M., Lakeman, A., Vandesompele, J., Hoebeeck, J., Van Maerken, T., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2660 · Cited by 279
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2387 · Cited by 266
Matthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.-C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3484 · Cited by 264
Cheung, N.-K. V., Cheung, I. Y., Kushner, B. H., Ostrovnaya, I., Chamberlain, E., Kramer, K., & Modak, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3807 · Cited by 263
ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
Hogarty, M. D., Norris, M. D., Davis, K., Liu, X., Evageliou, N. F., Hayes, C. S., Pawel, B., Guo, R., Zhao, H., Sekyere, E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6866 · Cited by 262
Schmidt, M. L., Lukens, J. N., Seeger, R. C., Brodeur, G. M., Shimada, H., Gerbing, R. B., Stram, D. O., Perez, C., Haase, G. M., & Matthay, K. K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1260 · Cited by 241
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., & Seeger, R. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj330 · Cited by 237
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, S. C., Wood, A. C., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 237
Strother, D. R., London, W. B., Schmidt, M. L., Brodeur, G. M., Shimada, H., Thorner, P., Collins, M. H., Tagge, E., Adkins, S., Reynolds, C. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9990 · Cited by 234
A population-based study of the usefulness of screening for neuroblastoma
Woods, W. G., Tuchman, M., Robison, L. L., Bernstein, M., Leclerc, J.-M., Brisson, L. C., Brossard, J., Hill, G., Shuster, J., Luepker, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)06020-5 · Cited by 231
Matthay, K. K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R. S., Ablin, A., Reynolds, C. P., Seeger, R. C., Weinberg, V. K., & Price, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.229 · Cited by 222
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0674 · Cited by 215
Yanik, G. A., Parisi, M. T., Shulkin, B. L., Naranjo, A., Kreissman, S. G., London, W. B., Villablanca, J. G., Maris, J. M., Park, J. R., Cohn, S. L., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112334 · Cited by 211
Self-citationGeorge, R. E., Li, S., Medeiros-Nancarrow, C., Neuberg, D., Marcus, K., Shamberger, R. C., Pulsipher, M., Grupp, S. A., & Diller, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6986 · Cited by 205
A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma
Riley, R. D., Heney, D., Jones, D. R., Sutton, A. J., Lambert, P. C., Abrams, K. R., Young, B., Wailoo, A. J., & Burchill, S. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1051-2 · Cited by 203
Nuchtern, J. G., London, W. B., Barnewolt, C. E., Naranjo, A., McGrady, P. W., Geiger, J. D., Diller, L., Schmidt, M. L., Maris, J. M., Cohn, S. L., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826cbbbd · Cited by 200
Matthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B., Twomey, E., Horn, B., Reynolds, C. P., Groshen, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6400 · Cited by 197
Vermeulen, J., De Preter, K., Naranjo, A., Vercruysse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G. P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70154-8 · Cited by 192
Schleiermacher, G., Mosseri, V, London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.375 · Cited by 192
Katzenstein, H. M., Bowman, L. C., Brodeur, G. M., Thorner, P. S., Joshi, V. V., Smith, E. I., Look, A. T., Rowe, S. T., Nash, M. B., Holbrook, T., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2007 · Cited by 190
Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Laverdière, C., Liu, Q., Yasui, Y., Nathan, P. C., Gurney, J. G., Stovall, M., Diller, L. R., Cheung, N.-K., Wolden, S., Robison, L. L., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp230 · Cited by 189
CHD5 , a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas
Fujita, T., Igarashi, J., Okawa, E. R., Gotoh, T., Manne, J., Kolla, V., Kim, J., Zhao, H., Pawel, B. R., London, W. B., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn176 · Cited by 188
Pritchard, J., Cotterill, S. J., Germond, S. M., Imeson, J., de Kraker, J., & Jones, D. R. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20219 · Cited by 183
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
Heukamp, L. C., Thor, T., Schramm, A., De Preter, K., Kumps, C., De Wilde, B., Odersky, A., Peifer, M., Lindner, S., Spruessel, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003967 · Cited by 181
Targeting ALK in neuroblastoma—preclinical and clinical advancements
Carpenter, E. L., & Mossé, Y. P. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.72 · Cited by 177
Passoni, L., Longo, L., Collini, P., Coluccia, A. M. L., Bozzi, F., Podda, M., Gregorio, A., Gambini, C., Garaventa, A., Pistoia, V., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4419 · Cited by 173
The epidemiology of neuroblastoma: a review
Heck, J. E., Ritz, B., Hung, R. J., Hashibe, M., & Boffetta, P. (2009) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2008.00983.x · Cited by 170
Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study
Haas-Kogan, D. A., Swift, P. S., Selch, M., Haase, G. M., Seeger, R. C., Gerbing, R. B., Stram, D. O., & Matthay, K. K. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)04506-6 · Cited by 170
Lashford, L. S., Lewis, I. J., Fielding, S. L., Flower, M. A., Meller, S., Kemshead, J. T., & Ackery, D. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1889 · Cited by 163
Neuroblastoma: Therapeutic strategies for a clinical enigma
Modak, S., & Cheung, N.-K. V. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.006 · Cited by 159
George, R. E., London, W. B., Cohn, S. L., Maris, J. M., Kretschmar, C. S., Diller, L., Brodeur, G. M., Castleberry, R. P., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.582 · Cited by 150
Schmidt, M. L., Lal, A., Seeger, R. C., Maris, J. M., Shimada, H., O’Leary, M., Gerbing, R. B., & Matthay, K. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.183 · Cited by 150
New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK
Barone, G., Anderson, J., Pearson, A. D. J., Petrie, K. R., & Chesler, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0680 · Cited by 144
Simon, T., Häberle, B., Hero, B., von Schweinitz, D., & Berthold, F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9339 · Cited by 143
Park, J. R., Scott, J. R., Stewart, C. F., London, W. B., Naranjo, A. H., Santana, V. M., Shaw, P. J., Cohn, S. L., & Matthay, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3293 · Cited by 142
Self-citationHenderson, T. O., Bhatia, R., Pinto, N. R., London, W. B., McGrady, P., Crotty, C., Sun, C., & Cohn, S. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6103 · Cited by 142
Yalçın, B., Kremer, L. C. M., & van Dalen, E. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub4 · Cited by 141
Update on diagnosis, treatment, and prognosis in opsoclonus–myoclonus–ataxia syndrome
Gorman, M. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833fde3f · Cited by 140
RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours
Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P. H., Voutilainen, R., Dahia, P. L. M., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204968 · Cited by 137
London, W. B., Frantz, C. N., Campbell, L., Seeger, R. C., Brumback, B., Cohn, S. L., Matthay, K. K., Castleberry, R. P., & Diller, L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5016 · Cited by 136
Bagatell, R., Popovic, M. B., London, W. B., Zhang, Y., Pearson, A. D. J., Matthay, K. K., Monclair, T. F., Ambros, P. F., & Cohn, S. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9184 · Cited by 136
Prognostic Impact of Gene Expression–Based Classification for Neuroblastoma
Oberthuer, A., Hero, B., Berthold, F., Juraeva, D., Faldum, A., Kahlert, Y., Asgharzadeh, S., Seeger, R., Scaruffi, P., Tonini, G. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3367 · Cited by 135
Bernardi, B. D., Mosseri, V., Rubie, H., Castel, V., Foot, A. B. M., Ladenstein, R. L., Laureys, G., Popovic, M. B., Lacerda, A., Pearson, A. D. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604640 · Cited by 132
Twist, C. J., Schmidt, M. L., Naranjo, A. H., London, W. B., Tenney, S. C., Marachelian, A., Shimada, H., Collins, M. H., Esiashvili, N., Adkins, E. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00919 · Cited by 131
Self-citationKushner, B. H., Wolden, S. L., LaQuaglia, M. P., Kramer, K., Verbel, D., Heller, G., & Cheung, N. V. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2821 · Cited by 128
Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., Klingebiel, T., & Berthold, F. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-21 · Cited by 128
Henderson, M. J., Haber, M., Porro, A., Munoz, M. A., Iraci, N., Xue, C., Murray, J. E., Flemming, C. L., Smith, J. L., Fletcher, J. I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr256 · Cited by 126
Efficacy of complete resection for high-risk neuroblastoma: a children’s cancer group study
Adkins, E. S., Sawin, R. S., Gerbing, R. B., London, W. B., Matthay, K. K., & Haase, G. M. (2004) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2004.02.041 · Cited by 123
Rare Variants in TP53 and Susceptibility to Neuroblastoma
Diskin, S. J., Capasso, M., Diamond, M. A., Oldridge, D. A., Conkrite, K. L., Bosse, K. R., Russell, M. R., Iolascon, A., Hakonarson, H. H., Devoto, M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju047 · Cited by 118
Mossé, Y. P., Deyell, R. J., Berthold, F., Nagakawara, A., Ambros, P. F., Monclair, T. F., Cohn, S. L., Pearson, A. D. J., London, W. B., & Matthay, K. K. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24777 · Cited by 114
Hartmann, O., Valteau‐Couanet, D., Vassal, G., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701737 · Cited by 110
Schulte, J. H., Bachmann, H. S., Brockmeyer, B., Preter, K. D., Oberthür, A., Ackermann, S., Kahlert, Y., Pajtler, K. W., Theißen, J., Westermann, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2809 · Cited by 107
Environmental risk factors for brain tumors
Connelly, J., & Malkin, M. G. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0032-4 · Cited by 105
Minturn, J. E., Evans, A. E., Villablanca, J. G., Yanik, G. A., Park, J. R., Shusterman, S., Groshen, S. G., Hellriegel, E. T., Bensen-Kennedy, D. M., Matthay, K. K., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1581-4 · Cited by 105
Self-citationCohen, L. E., Gordon, J. H., Popovsky, E. Y., Gunawardene, S. C., Duffey-Lind, E. C., Lehmann, L., & Diller, L. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.218 · Cited by 104
Preter, K. D., Vermeulen, J., Brors, B., Delattre, O., Eggert, A., Fischer, M., Janoueix‐Lerosey, I., Lavarino, C. E., Maris, J. M., Mora, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2607 · Cited by 100
(SFCE), O. B. O. T. S. F. D. C. D. L., Schleiermacher, G., Michon, J. M., Huon, I., d’Enghien, C. D., Klijanienko, J., Brisse, H. J., Ribeiro, A., Mosseri, V., Rubie, H., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603820 · Cited by 96
Liu, Z., Yang, X., Li, Z., McMahon, C., Sizer, C., Barenboim‐Stapleton, L., Bliskovsky, V., Mock, B. A., Ried, T., London, W. B., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2010.187 · Cited by 96
Preter, K. D., Mestdagh, P., Vermeulen, J., Zeka, F., Naranjo, A. H., Bray, I. M., Castel, V., Chen, C., Drożyńska, E., Eggert, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0610 · Cited by 95
Childhood Cancer: Overview of Incidence Trends and Environmental Carcinogens
Zahm, S. H., & Devesa, S. S. (1995) · Environmental Health Perspectives · doi:10.1289/ehp.95103s6177 · Cited by 93
Garaventa, A., Luksch, R., Biasotti, S., Severi, G., Pizzitola, M. R., Viscardi, E., Prete, A., Mastrangelo, S., Podda, M. G., Haupt, R., et al. (2003) · Cancer · doi:10.1002/cncr.11797 · Cited by 90
Imaging the Norepinephrine Transporter in Neuroblastoma: A Comparison of [18F]-MFBG and 123I-MIBG
Zhang, H., Huang, R., Cheung, N. V., Guo, H.-F., ZANZONICO, P. B., Thaler, H. T., Lewis, J. S., & Blasberg, R. G. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1153 · Cited by 87
Morgenstern, D. A., Baruchel, S., & Irwin, M. S. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318299d637 · Cited by 86
Self-citationCole, K. A., & Maris, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1409 · Cited by 84
Messina, J. A., Cheng, S., Franc, B. L., Charron, M., Shulkin, B. L., To, B., Maris, J. M., Yanik, G. A., Hawkins, R. A., & Matthay, K. K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20777 · Cited by 84
Cohn, S. L., Look, A. T., Joshi, V. V., Holbrook, T., Salwen, H. R., Chagnovich, D., Chesler, L., Rowe, S. T., Valentine, M. B., & Komuro, H. (1995) · PubMed · Cited by 80
Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.
Maris, J. M., Weiss, M. J., Mossé, Y. P., Hii, G., Guo, C. H., White, P. S., Hogarty, M. D., Mirensky, T. L., Brodeur, G. M., Rebbeck, T. R., et al. (2002) · PubMed · Cited by 80
George, R. E., Lahti, J. M., Adamson, P. C., Zhu, K., Finkelstein, D., Ingle, A. M., Reid, J. M., Krailo, M., Neuberg, D. S., Blaney, S. M., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22607 · Cited by 79
Yamamoto, K., Ohta, S., Ito, E., Hayashi, Y., Asami, T., Mabuchi, O., Higashigawa, M., & Tanimura, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1209 · Cited by 79
Xu, Y., Sun, J., Sheard, M. A., Tran, H. C., Wan, Z., Liu, W. Y., Asgharzadeh, S., Sposto, R., Wu, H. W., & Seeger, R. C. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1466-y · Cited by 75
Buckley, P. G., Alcock, L., Bryan, K. R., Bray, I. M., Schulte, J. H., Schramm, A. R., Eggert, A., Mestdagh, P., Preter, K. D., Vandesompele, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3215 · Cited by 74
Targeting Histone Deacetylases in Neuroblastoma
Witt, O., Deubzer, H. E., Lodrini, M., Milde, T., & Oehme, I. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315774 · Cited by 70
N-myc and Noncoding RNAs in Neuroblastoma
Buechner, J., & Einvik, C. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0244 · Cited by 68
A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
García, I., Mayol, G., Ríos, J., Doménech, G., Cheung, N. V., Oberthuer, A., Fischer, M., Maris, J. M., Brodeur, G. M., Hero, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2483 · Cited by 67
DuBois, S. G., London, W. B., Zhang, Y., Matthay, K. K., Monclair, T. F., Ambros, P. F., Cohn, S. L., Pearson, A. D. J., & Diller, L. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21684 · Cited by 66
Angiogenesis as a target in neuroblastoma
Rössler, J. K., Taylor, M., Geoerger, B., Farace, F., Lagodny, J., Peschka‐Süss, R., Niemeyer, C. M., & Vassal, G. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.015 · Cited by 65
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon, T., Spitz, R., Faldum, A., Hero, B., & Berthold, F. (2004) · PubMed · Cited by 65
Giannatale, A. D., Dias, N., Devos, A. S., Hugh, K. M., Boubaker, A., Courbon, F., Verschuur, A., Ducassoul, S., Malekzadeh, K., Casanova, M., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.012 · Cited by 62
Clausen, N., Andersson, P., & Tommerup, N. (1989) · Acta Paediatrica · doi:10.1111/j.1651-2227.1989.tb11135.x · Cited by 61
Goldsmith, K. C., Lestini, B. J., Gross, M., Ip, L. R. H., Bhumbla, A., Zhang, X., Zhao, H., Liu, X., & Hogarty, M. D. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.171 · Cited by 57
Yalçın, B., Kremer, L. C. M., Caron, H. N., & van Dalen, E. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub3 · Cited by 49
MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Barone, G., Tweddle, D. A., Shohet, J. M., Chesler, L., Moreno, L., Pearson, A. D. J., & Maerken, T. V. (2014) · Current Drug Targets · doi:10.2174/13894501113149990194 · Cited by 48
Nowacki, S., Skowron, M., Oberthuer, A., Fagin, A., Voth, H., Brors, B., Westermann, F., Eggert, A., Hero, B., Berthold, F., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210996 · Cited by 47
Long‐term follow‐up of children with high‐risk neuroblastoma: The ENSG5 trial experience
Moreno, L., Vaidya, S. J., Pinkerton, R., Lewis, I. J., Imeson, J., Machin, D., Pearson, A. D. J., & on behalf of the European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG) (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24452 · Cited by 47
Likelihood of Bone Recurrence in Prior Sites of Metastasis in Patients With High-Risk Neuroblastoma
Polishchuk, A. L., Li, R., Hill‐Kayser, C. E., Little, A., Hawkins, R. A., Hamilton, J., Lau, M., Tran, H. C., Strahlendorf, C., Lemons, R. S., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.004 · Cited by 44
Meany, H. J., London, W. B., Ambros, P. F., Matthay, K. K., Monclair, T. F., Simon, T., Garaventa, A., Berthold, F., Nakagawara, A., Cohn, S. L., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25134 · Cited by 42
Self-citationGermline gain-of-function mutations of ALK disrupt central nervous system development
de Pontual, L., Kettaneh, D., Gordon, C. T., Oufadem, M., Boddaert, N., Lees, M. M., Balu, L., Lachassinne, E., Petros, A., Mollet, J., et al. (2011) · Human Mutation · doi:10.1002/humu.21442 · Cited by 42
Stricker, T. P., Morales La Madrid, A., Chlenski, A., Guerrero, L., Salwen, H. R., Gosiengfiao, Y., Perlman, E. J., Furman, W., Bahrami, A., Shohet, J. M., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.010 · Cited by 36
Self-citationLongo, L., Panza, E., Schena, F., Seri, M., Devoto, M., Romeo, G. C., Bini, C., Pappalardo, G., Tonini, G. P., & Perri, P. (2007) · Human Heredity · doi:10.1159/000099997 · Cited by 36
Koehn, T. A., Trimble, L. L., Alderson, K. L., Erbe, A. K., McDowell, K. A., Grzywacz, B. J., Hank, J. A., & Sondel, P. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00091 · Cited by 35
Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Heczey, A. A., & Louis, C. U. (2013) · PubMed · Cited by 34
Johnson, K. A., Aplenc, R., & Bagatell, R. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22825 · Cited by 34
Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors
Bender, J. G., Yamashiro, D. J., & Fox, E. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0148 · Cited by 25
Screening for neuroblastoma: a resurrected idea?
Maris, J. M., & Woods, W. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60500-0 · Cited by 23
Bender, J. G., Blaney, S. M., Borinstein, S. C., Reid, J. M., Baruchel, S., Ahern, C. H., Ingle, A. M., Yamashiro, D. J., Chen, A. P., Weigel, B. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0078 · Cited by 22
Self-citationdic(4; 17)(p11;p11): A new recurrent chromosomal abnormality in chronic b-lymphoid disorders
Callet‐Bauchu, E., Rimokh, R., Tigaud, I., Pagès, J., Gazzo, S., Bastion, Y., Sebban, C., Magaud, J., Coiffier, B., & Felman, P. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199611)17:3<156::aid-gcc3>3.0.co;2-3 · Cited by 17
Rossbach, H., Baschinsky, D. Y., Wynn, T., Obzut, D. A., Sutcliffe, M. J., & Tebbi, C. K. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21219 · Cited by 16
Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
Weiser, D. A., Laudenslager, M., Rappaport, E. R., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., London, W. B., Maris, J. M., & Mossé, Y. P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.9514 · Cited by 13
Cited by
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494
Self-citationOverview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 394
Park, J. R., Bagatell, R., Cohn, S. L., Pearson, A. D., Villablanca, J. G., Berthold, F., Burchill, S., Boubaker, A., McHugh, K., Nuchtern, J. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0177 · Cited by 365
Self-citationPark, J. R., Kreissman, S. G., London, W. B., Naranjo, A., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D., Shaw, P. J., Kraveka, J. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.11642 · Cited by 358
Self-citationNeuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Metadata
- Authors
- Irwin, M. S., & Park, J. R.
- Venue
- Pediatric Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 62
- Issue
- 1
- Pages
- 225-256
- ISSN
- 0031-3955 (ISSN-L)
- OpenAlex
- W145418528
- Cited by
- 392
- References
- 163
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.